We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bradmer Pharmaceuticals | TSXV:BMR.H | TSX Venture | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
Bradmer Pharmaceuticals Inc. (the "Corporation") (TSX VENTURE:BMR.H) announced today that Perry N. Dellelce has resigned as a director of the Corporation. He will continue to act as a consultant to the Corporation. The Corporation thanks Mr. Dellelce for his commitment and significant past contribution to the Corporation. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. FOR FURTHER INFORMATION PLEASE CONTACT: Bradmer Pharmaceuticals Inc. Paul Van Damme Chief Financial Officer 416.847.6905
1 Year Bradmer Pharmaceuticals Chart |
1 Month Bradmer Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
